New drug duo offers hope for hard-to-treat lymphoma patients
NCT ID NCT04512534
First seen Apr 03, 2026 · Last updated May 01, 2026 · Updated 3 times
Summary
This study tests a combination of two drugs—sintilimab and chidamide—in about 51 adults with a rare blood cancer called peripheral T-cell lymphoma that has returned or not improved after prior therapy. The goal is to see if the combination can control the cancer longer and with manageable side effects. Participants receive both drugs intravenously and orally, and are monitored for tumor response and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Dongmei Ji
RECRUITINGShanghai, Shanghai Municipality, 021, China
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.